— Know what they know.
Not Investment Advice

CTLT NYSE

Catalent, Inc.
1W: +2.0% 1M: +7.4% 3M: +5.2% 1Y: +53.0% 3Y: -48.1% 5Y: +21.6%
$63.48
Last traded 2024-12-17 — delisted
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · $11.5B mcap · 180M float · 1.24% daily turnover

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$4.4B +2.5% ▲
5Y CAGR: +11.7%
Gross Profit
$953M -10.1% ▼
5Y CAGR: +3.4%
Operating Income
-$749M -446.7% ▼
Net Income
-$1.0B -349.6% ▼
EPS (Diluted)
$-5.76 -350.0% ▼
EBITDA
-$284M -206.8% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$3.1B$4.0B$4.8B$4.3B$4.4B
YoY Growth+22.9%+29.2%+20.8%-11.4%+2.5%
Cost of Revenue$2.1B$2.6B$3.2B$3.2B$3.4B
Gross Profit$983M$1.4B$1.6B$1.1B$953M
Gross Margin31.8%33.8%34.0%24.8%21.8%
R&D Expenses$64M$21M$23M$18M$0
SG&A Expenses$578M$687M$844M$831M$935M
Operating Expenses$578M$706M$885M$987M$1.7B
Operating Income$144M$354M$349M-$137M-$749M
Operating Margin4.6%8.9%7.2%-3.2%-17.1%
Interest Expense$126M$110M$123M$186M$254M
Income Before Tax$260M$715M$605M-$315M-$1.0B
Tax Expense$40M$130M$86M-$83M$16M
Net Income$173M$585M$499M-$232M-$1.0B
Net Margin5.6%14.6%10.3%-5.4%-23.8%
EPS (Diluted)$1.14$3.11$2.71$-1.28$-5.76
EBITDA$640M$1.1B$1.1B$266M-$284M
Shares Outstanding152M170M178M181M181M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms